You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD22

Showing 26 - 50 of 7,848
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Beijing, Tianjin (LCAR-AIO cells product)

Recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • LCAR-AIO cells product
  • Beijing, Beijing, China
  • +1 more
Apr 1, 2022

B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22

Recruiting
  • B Cell Leukemias
  • B Cell Lymphomas
  • CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 19, 2022

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Lymphoma, B-Cell Trial in Xi'an (Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy)

Terminated
  • Lymphoma, B-Cell
  • Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy
  • Xi'an, Shaanxi, China
    Second Affiliated Hospital of Xi'an Jiaotong University
Oct 28, 2021

Acute Lymphoblastic Leukemia Trial (inotuzumab ozogamicin)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • inotuzumab ozogamicin
  • (no location specified)
Jan 6, 2023

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,

Completed
  • B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 25, 2022

Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive Trial in Monrovia,

Recruiting
  • Blasts 5 Percent or More of Bone Marrow Nucleated Cells
  • +4 more
  • ADCT-602
  • Monrovia, California
  • +1 more
Dec 7, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

B-cell Acute Lymphoblastic Leukemia Trial in France, United States (UCART22)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • UCART22
  • CLLS52
  • Los Angeles, California
  • +10 more
Sep 23, 2022

B-ALL Trial in Kunming (CD19 and CD22 targeted prime CAR-T cells)

Recruiting
  • B-ALL
  • CD19 and CD22 targeted prime CAR-T cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

B Cell Lymphoma Trial in Kunming (CD19 and CD22 targeted prime CAR- T cells)

Recruiting
  • B Cell Lymphoma
  • CD19 and CD22 targeted prime CAR- T cells
  • Kunming, Yunnnan, China
    920th Hospital of Joint Logistics Support Force
Jul 30, 2021

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/22 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/22 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 21, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

B-cell Non-Hodgkin's Lymphoma Trial (Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell

Not yet recruiting
  • B-cell Non-Hodgkin's Lymphoma
  • Fully Human Anti-CD19/CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection
  • (no location specified)
Oct 12, 2021

Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5

Withdrawn
  • Allogeneic Hematopoietic Stem Cell Transplantation Recipient
  • +7 more
  • Inotuzumab Ozogamicin
  • +2 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jan 13, 2022

Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)

Unknown status
  • Leukemia
  • Lymphoma
  • Anti-CD22-CAR-transduced T cells
  • Beijing, Beijing, China
    Fengtai District
Feb 6, 2021

Solid Tumor, Adult, Cervical Cancer, Sarcoma Trial in Shijiazhuang (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Recruiting
  • Solid Tumor, Adult
  • +3 more
  • Autologous aPD-L1 armored anti-CD22 CAR T cells
  • Shijiazhuang, Hebei, China
    Fourth Hospital of Hebei Medical University
May 25, 2021

B-cell Malignancy Trial in Xuzhou (ThisCART22 cells)

Recruiting
  • B-cell Malignancy
  • ThisCART22 cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Nov 9, 2021

Leukemia Trial in Bronx (deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins)

Completed
  • Leukemia
  • deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins
  • Bronx, New York
    Albert Einstein Cancer Center at Albert Einstein College of Medi
Apr 9, 2021

Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in United Kingdom, United States (AUTO3)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • AUTO3
  • Duarte, California
  • +10 more
Oct 19, 2022

CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Houston (Inotuzumab

Terminated
Has Results
  • CD22 Positive
  • +2 more
  • Inotuzumab Ozogamicin
  • Houston, Texas
    M D Anderson Cancer Center
Mar 17, 2021

B-Cell Leukemia, B-Cell Lymphoma Trial in Guangzhou (4SCAR19/22 T cells, Interleukin-2)

Suspended
  • B-Cell Leukemia
  • B-Cell Lymphoma
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Aug 9, 2021